Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Helicobacter Pylori Vaccine Completes Phase III Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

According to China's Ministry of Science and Technology, the Third Military Medical University of the PLA has successfully developed an oral recombinant Helicobacter pylori vaccine. The world's first such vaccine, the product has completed Phase III clinical trials and obtained the country's new drug certification. Trial results showed the vaccine to be effective and safe, with a protection rate of 72 percent in preventing H. pylori infection. The bacteria, which afflict some 50 percent of people in developing countries, cause gastric ulcers and show close correlation with stomach cancer. The developer of the vaccine, along with investors, are working hard to bring it to market as soon as possible. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071452

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel